635-22-3

应用筛选条件

关键词:'635-22-3'

显示 1-4 共 4 条结果关于 "635-22-3" 范围论文

Tracing lysozyme-lipid interactions with long-wavelength squaraine dyes.

Valeriya M Ioffe et al.

Journal of fluorescence, 17(1), 65-72 (2006-12-29)

The applicability of the two newly commercial available squaraine labels Square-670-NHS and Seta-635-NHS to exploring protein-lipid interactions has been evaluated. The labels were conjugated to lysozyme (Lz) (squaraine-lysozyme conjugates below referred to as Square-670-Lz and Seta-635-Lz), a structurally well-characterized small

Phosphorylation of caldesmon at sites between residues 627 and 642 attenuates inhibitory activity and contributes to a reduction in Ca2+-calmodulin affinity.

Svetlana S Hamden et al.

Biophysical journal, 99(6), 1861-1868 (2010-09-23)

Caldesmon is an actin- and myosin-binding protein found in smooth muscle that inhibits actin activation of myosin ATPase activity. The activity of caldesmon is controlled by phosphorylation and by binding to Ca(2+)-calmodulin. We investigated the effects of phosphorylation by p(21)-activated

In vitro comparison of hypericin and 5-aminolevulinic acid-derived protoporphyrin IX for photodynamic inactivation of medulloblastoma cells.

Rainer Ritz et al.

PloS one, 7(12), e51974-e51974 (2012-12-20)

Hypericin (HYP) is a naturally occurring photosensitizer. Cellular uptake and photodynamic inactivation after incubation with this photosensitizer have neither been examined in medulloblastoma cells in vitro, nor compared with 5-aminolevulinic acid-derived protoporphyrin IX (5-ALA-derived PpIX). In 3 medulloblastoma cell lines

Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.

Emily Li et al.

The Cochrane database of systematic reviews, 5, CD012208-CD012208 (2020-05-07)

Age-related macular degeneration (AMD) is one of the leading causes of permanent blindness worldwide. The current mainstay of treatment for neovascular AMD (nAMD) is intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents: aflibercept, ranibizumab, and off-label bevacizumab. Injections can

1/1